U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19ClN2S.ClH
Molecular Weight 355.3267
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPROMAZINE HYDROCHLORIDE

SMILES

CN(C)CCCN1c2ccccc2Sc3ccc(cc31)Cl.Cl

InChI

InChIKey=FBSMERQALIEGJT-UHFFFAOYSA-N
InChI=1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

Originator

Curator's Comment:: Chlorpromazine was synthesized in December 1951 in the laboratories of Rhône-Poiulenc, and became available on prescription in France in November 1952.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Primary
THORAZINE

Approved Use

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Launch Date

-3.82319985E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
37.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.31 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
135 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
247 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
81.8 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.1 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.05 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.48 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.52 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPROMAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
CHLORPROMAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 75 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 52 years (range: 36.5-65.6 years)
Health Status: unhealthy
Condition: agitation
Age Group: 52 years (range: 36.5-65.6 years)
Sex: M+F
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Other AEs: Adverse event...
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Adverse event grade 5
25 mg 1 times / day multiple, intramuscular
Dose: 25 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, Elderly Patients
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: Elderly Patients
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE.
1964 Apr
A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.
1992
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
1992
Chlorpromazine: a drug potentially useful for treating mycobacterial infections.
1992
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
1992 Apr 10
An unusual cause of convulsions in a newborn infant.
1992 Dec
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
1992 Jul
Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens.
1992 Mar
[A case of neuroleptic malignant syndrome with acute renal failure].
1992 Nov
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii.
2003 Aug 1
Dual action of oestrogens on the mouse constitutive androstane receptor.
2003 Dec 1
[Reversal of multidrug resistance in leukemic cell line K562/AO2 by chlordelazine in vitro].
2003 Jul
QTc prolongation: chlorpromazine and high-dosage olanzapine.
2003 Jun
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
2003 Jun
The steroid-responsive hiccup reflex arc: competitive binding to the corticosteroid-receptor?
2003 Jun-Aug
Variant Creutzfeldt-Jakob disease.
2003 Mar
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.
2003 May 10
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
2003 Oct
Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis.
2003 Oct 24
Sydenham's chorea may be a risk factor for drug induced parkinsonism.
2003 Sep
[Differences in prooxidant effect of neuroleptics haloperidol and aminazine].
2003 Sep-Oct
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.
2004 Apr
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.
2004 Apr 15
Two cases of deep vein thrombosis associated with antipsychotic drug use.
2004 Aug
Valproate-induced hyperammonemic encephalopathy.
2004 Aug
Effects of lipopolysaccharide and chlorpromazine on glucocorticoid receptor-mediated gene transcription and immunoreactivity: a possible involvement of p38-MAP kinase.
2004 Dec
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
2004 Jan
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?
2004 Mar
Drug-induced liver injury.
2004 Mar 1
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.
2004 May
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.
2004 May 1
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
2004 Oct
Oral terbutaline in the management of pharmacologically induced prolonged erection.
2004 Oct
The phenothiazine drugs inhibit hERG potassium channels.
2005
Intraoperative preparation of the radial artery for coronary artery bypass grafting.
2005
Invited review: fluphenazine augments retinal oxidative stress.
2005 Aug
Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells.
2005 Aug 4
Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland.
2005 Feb
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
2005 Jun
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
2005 Mar 7
[Thanatogenesis in poisoning with psychopharmaceuticals].
2005 Mar-Apr
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
2005 May
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.
2005 Nov
The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system.
2005 Sep 1
Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases.
2006 Apr
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.
2006 Apr 15
Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.
2006 Feb 1
Frequency of high-risk use of QT-prolonging medications.
2006 Jun
Patents

Sample Use Guides

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day
Route of Administration: Other
In Vitro Use Guide
Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:30 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:30 UTC 2021
Record UNII
9WP59609J6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPROMAZINE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [JAN]
Common Name English
10-(3-DIMETHYLAMINOPROPYL)-2-CHLOROPHENOTHIAZINE MONOHYDROCHLORIDE
Systematic Name English
CHLORPROMAZINE HYDROCHLORIDE [VANDF]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [WHO-DD]
Common Name English
NCI-C05210
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [EP]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [USP-RS]
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-, MONOHYDROCHLORIDE
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
2-CHLORO-10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE MONOHYDROCHLORIDE
Systematic Name English
CHLORPROMAZINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
CHLORPROMAZINE HCL
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [MART.]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
KLORPROMAN
Common Name English
PROMAPAR
Brand Name English
NORCOZINE
Common Name English
SONAZINE
Brand Name English
CHLORPROMAZINE HYDROCHLORIDE [WHO-IP]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
CHLORPROMAZINE HYDROCHLORIDE [MI]
Common Name English
MARAZINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C740
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
EPA PESTICIDE CODE 600006
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C47975
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
DRUG BANK
DBSALT000026
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
FDA UNII
9WP59609J6
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
CAS
69-09-0
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
USP_CATALOG
1125006
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY USP-RS
WHO INTERNATIONAL PHARMACOPEIA
CHLORPROMAZINE HYDROCHLORIDE
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY Description: A white or slightly creamy white, crystalline powder; odour, slight.Solubility: Soluble in 0.4 part of water; freely soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Neuroleptic.Storage: Chlorpromazine hydrochloride should be kept in a tightly closed container, protected from light.
PUBCHEM
6240
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
EPA CompTox
69-09-0
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
EVMPD
SUB01255MIG
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-701-3
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
MERCK INDEX
M3461
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY Merck Index
RXCUI
104728
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL71
Created by admin on Fri Jun 25 20:53:31 UTC 2021 , Edited by admin on Fri Jun 25 20:53:31 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY